PMID- 33378085
OWN - NLM
STAT- MEDLINE
DCOM- 20210514
LR  - 20220531
IS  - 1525-1470 (Electronic)
IS  - 0736-8046 (Linking)
VI  - 38
IP  - 1
DP  - 2021 Jan
TI  - Cutaneous reactions to pediatric cancer treatment part II: Targeted therapy.
PG  - 18-30
LID - 10.1111/pde.14495 [doi]
AB  - Cancer remains a leading cause of morbidity and mortality among children. 
      Targeted therapies may improve survivorship; however, unique side-effect profiles 
      have also emerged with these novel therapies. Changes in hair, skin, and 
      nails-termed dermatologic adverse events (AEs)-are among the most common sequelae 
      and may result in interruption or discontinuation of therapy. Though dermatologic 
      AEs have been detailed in adults, these findings are not well described in the 
      pediatric population. We reviewed the literature to characterize dermatologic AEs 
      to anticancer targeted therapies available as of July 2020 and summarized the 
      spectrum of clinical findings as well as treatment recommendations for children. 
      Dermatologic AEs are among the most common AEs reported in pediatric patients 
      receiving targeted therapy, but morphologic and histologic descriptions are often 
      lacking in current publications. Pediatric dermatologists are uniquely poised to 
      recognize specific morphology of dermatologic AEs and make recommendations for 
      prevention and treatment that may improve quality of life and enable ongoing 
      cancer therapy.
CI  - (c) 2020 Wiley Periodicals LLC.
FAU - Carlberg, Valerie M
AU  - Carlberg VM
AUID- ORCID: 0000-0002-1581-7967
AD  - Children's Wisconsin, Milwaukee, WI, USA.
AD  - Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Davies, Olivia M T
AU  - Davies OMT
AUID- ORCID: 0000-0001-5428-7279
AD  - Medical College of Wisconsin, Milwaukee, WI, USA.
FAU - Brandling-Bennett, Heather A
AU  - Brandling-Bennett HA
AD  - Seattle Children's Hospital, Seattle, WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Leary, Sarah E S
AU  - Leary SES
AD  - Seattle Children's Hospital, Seattle, WA, USA.
AD  - University of Washington, Seattle, WA, USA.
FAU - Huang, Jennifer T
AU  - Huang JT
AD  - Boston Children's Hospital, Boston, MA, USA.
AD  - Harvard Medical School, Boston, MA, USA.
FAU - Coughlin, Carrie C
AU  - Coughlin CC
AUID- ORCID: 0000-0002-2760-1725
AD  - St Louis Children's Hospital, St. Louis, MO, USA.
AD  - Washington University School of Medicine in St. Louis, St. Louis, MO, USA.
FAU - Gupta, Deepti
AU  - Gupta D
AD  - Seattle Children's Hospital, Seattle, WA, USA.
AD  - University of Washington, Seattle, WA, USA.
LA  - eng
PT  - Journal Article
PT  - Review
DEP - 20201230
PL  - United States
TA  - Pediatr Dermatol
JT  - Pediatric dermatology
JID - 8406799
RN  - 0 (Antineoplastic Agents)
SB  - IM
MH  - *Antineoplastic Agents/adverse effects
MH  - Child
MH  - Humans
MH  - Molecular Targeted Therapy/adverse effects
MH  - *Neoplasms/drug therapy
MH  - Quality of Life
MH  - Skin
OTO - NOTNLM
OT  - adverse reactions
OT  - cutaneous toxicity
OT  - oncodermatology
OT  - pediatric
OT  - targeted therapy
EDAT- 2020/12/31 06:00
MHDA- 2021/05/15 06:00
CRDT- 2020/12/30 12:42
PHST- 2020/12/31 06:00 [pubmed]
PHST- 2021/05/15 06:00 [medline]
PHST- 2020/12/30 12:42 [entrez]
AID - 10.1111/pde.14495 [doi]
PST - ppublish
SO  - Pediatr Dermatol. 2021 Jan;38(1):18-30. doi: 10.1111/pde.14495. Epub 2020 Dec 30.